SBIR Phase I: EEG-guided intelligent transcranial photobiomodulation to reduce symptoms of autism

这个小企业创新研究（SBIR）第一阶段项目旨在展示一种可穿戴设备的概念验证，该设备可提供个性化治疗，以减轻儿童自闭症。在美国，每44个孩子中就有一个被诊断患有自闭症。没有药物或器械治疗的行为疗法显示出混合效果。该项目提出了一种有效的个性化治疗方法，以增强或取代实践状态。该设备将在每个孩子的家中使用，而不需要专家。该系统的好处是自闭症症状改善了大约33%，为每个孩子一生节省了100多万美元。该SBIR一期项目旨在证明一种无创可穿戴医疗设备的可行性，该设备在经颅光生物调节（tPBM）中使用近红外辐射刺激脑组织，并对Delta脑电波进行集成EEG反馈，指示治疗效果。该项目将完成适合使用系统的原型设计，收集儿童临床前数据，开发信号分析数据库，并根据患者的基线因素开发算法，以达到预期效果。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

This Small Business Innovation Research (SBIR) Phase I project aims to demonstrate proof of concept for a wearable device for delivering personalized therapy to mitigate autism in children. One out of 44 children in America is diagnosed with autism. Behavioral therapies with no pharmacological or device treatments show mixed effects. This project advances an effective personalized treatment to augment or replace the state of practice. The device will be used in the privacy of each child’s home without the need for a specialist. The benefit of the proposed system is approximately 33% improvement in autism symptoms, resulting in over $1 million in lifetime savings for each child. This SBIR Phase I project aims to demonstrate the feasibility of a non invasive wearable medical device that stimulates brain tissue using near infrared radiation in Transcranial Photobiomodulation (tPBM), with integrated EEG feedback on Delta brain waves indicative of therapeutic effect. This project will complete prototyping of a system suitable for use, collect pre-clinical data in children, develop a signal analysis database, and develop algorithms based on the patient’s baseline factors for the desired effect.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.